Desoxycorticosterone Pivalate Duration of Action and Individualized Dosing Intervals in Dogs with Primary Hypoadrenocorticism

BACKGROUND: Clinicians alter dosing for desoxycorticosterone pivalate (DOCP) to mitigate costs, but this practice has not been critically evaluated in a prospective clinical trial. HYPOTHESIS/OBJECTIVES: The duration of action of DOCP is longer than 30 days in dogs with primary hypoadrenocorticism (...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaffey, J.A., Nurre, P., Cannon, A.B., DeClue, A.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697171/
https://www.ncbi.nlm.nih.gov/pubmed/28892205
http://dx.doi.org/10.1111/jvim.14828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697171/
https://www.ncbi.nlm.nih.gov/pubmed/28892205
http://dx.doi.org/10.1111/jvim.14828

Ejemplares similares